Posted by Michael Wonder on 29 Nov 2022
Leo Pharma’s Adtralza approved by MHRA, EC for adolescent atopic dermatitis
29 November 2022 - The MHRA and the European Commission have approved a change to the terms of the marketing authorisation for Leo Pharma’s Adtralza (tralokinumab) to include the treatment of adolescent patients between 12 and 17 years of age with moderate to severe atopic dermatitis, who are candidates for systemic therapy.
The approval comes at a critical time: approximately 6% of adolescents within this newly approved age group suffer from atopic dermatitis in the UK.
